Intravenous peramivir for treatment of influenza in hospitalized patients

Antiviral Therapy

Volumn 19, Issue 4, 2014, Pages 349-361

  Ison, Michael G ^a   Fraiz, Joseph ^b   Heller, Barry ^c   Jauregui, Luis ^d   Mills, Graham ^e   O'Riordan, William ^f   O'Neil, Brian ^g   Playford, E Geoffrey ^h   Rolf, J Douglass ⁱ   Sada Diaz, Eduardo ^j   Elder, Jenna ^k   Collis, Phil ^l   Hernandez, Jaime E ^l   Sheridan, William P ^l  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Infectious Diseases of Indiana   (United States)

^c Novellus Research   (United States)

^d ST VINCENT MERCY MEDICAL CENTER   (United States)

^e WAIKATO HOSPITAL   (New Zealand)

^f EStudySite   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ Interior Health Authority   (Canada)

^j INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^k Pharpoint Research   (United States)

^l BIOCRYST PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; OXYGEN SUPPLY; PANDEMIC INFLUENZA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; VIRUS DETECTION; VIRUS ISOLATION; VIRUS TITRATION; YOUNG ADULT; AGED; CLINICAL TRIAL; HOSPITALIZATION; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; VIRUS LOAD; VIRUS SHEDDING;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYCLOPENTANES; FEMALE; GUANIDINES; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD; VIRUS SHEDDING; YOUNG ADULT;

EID: 84924931262     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2680     Document Type: Article

References (37)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-1340.
2. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses 2009; 3:37-49.
3. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-1719.
4. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 2011; 52 Suppl 1:S75-S82.
5. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr 2010; 2:RRN1153.
6. Hernandez JE, Grainger J, Simonsen L, Collis P, Edelman L, Sheridan WP. Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment. Influenza Other Respir Viruses 2012; 6:305-308.
7. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 2012; 17:143-157.
8. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-257.
9. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-1041.
10. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83:10366-10373.
11. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803-2812.
12. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568-4574.
13. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267-5276.
14. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2012; 18:651-661.
15. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 2002; 54:143-147.
16. Boltz DA, Aldridge JR, Jr., Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010; 70:1349-1362.
17. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52:695-706.
18. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:2204-2207.
19. Bantia S, Kellog D, Parker C, Upshaw R, Illyushina NA, Babu YS. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antiviral Res 2011; 90:17-21.
20. Gubareva LV, Trujillo AA, Okomo-Adhiambo M, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010; 15:1151-1159.
21. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24:67-76.
22. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41:742-750.
23. Bazan JA, Bauer KA, Hollister AS, et al. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy. Pharmacotherapy 2010; 30:1016-1020.
24. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279:1452-1457.
25. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-1944.
26. Skarbinski J, Jain S, Bramley A, et al. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States-September- October 2009. Clin Infect Dis 2011; 52 Suppl 1:S50-S59.
27. Centers for Disease Control and Prevention. Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901-908.
28. Ison MG, Riordan W, Elder J, Collis PJ, Hernandez JE. Comparison of tissue culture infective dose (TCID50) and quantitative PCR (QPCR) for diagnosis and follow up of influenza in hospitalized subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2011, Chicago, IL, USA. Abstract V-1556.
29. Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654-1662.
30. Lee N, Chan PK, Wong CK, et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237-247.
31. Petersen E, Keld DB, Ellermann-Eriksen S, et al. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 2011; 43:495-503.
32. Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 Influenza A virus. Clin Infect Dis 2012; 55:1-7.
33. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. PLoS One 2012; 7: e40261.
34. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012; 56:369-377.
35. Thomas B, Hollister AS, Muczynski KA. Peramivir clearance in continuous renal replacement therapy. Hemodial Int 2010; 14:339-340.
36. Beigel J, Harman LA, Collis P, et al. Pharmacokinetic and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract A-1408.
37. US Food and Drug Administration. Emergency use authorization of peramivir IV fact sheet for health care providers. US Department of Health and Human Services. (Accessed 26 May 2014.) Available from http://www.fda.gov/downloads/ Drugs/DrugSafety/PostMarketDrugSafetyInformationforPatientsandProviders/ UCM187811.pdf